LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 199.73M -75.7% |
| Revenue (ttm) | 20.99M |
| Net Income | -109.00M |
| EPS | -3.66 |
| Shares Out | 31.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,883 |
| Open | 6.43 |
| Previous Close | 6.34 |
| Day's Range | 6.38 - 6.64 |
| 52-Week Range | 6.29 - 50.40 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 32.00 (+402.36%) |
| Earnings Date | Jul 29, 2026 |
About LENZ
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 402.36% from the latest price.
News
Lenz announces Everest Medicines acquired rights to develop VIZZ in China
LENZ Therapeutics (LENZ) announced that Everest Medicines has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize VIZZ...
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 The New Drug Application for LNZ100 in China was submitted September 2025 with approval a...
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmol...
Lenz Therapeutics price target lowered to $20 from $26 at Citi
Citi lowered the firm’s price target on Lenz Therapeutics (LENZ) to $20 from $26 and keeps a Buy rating on the shares.
LENZ Therapeutics trading halted, volatility trading pause
09:33 EDT LENZ Therapeutics (LENZ) trading halted, volatility trading pause
LENZ Therapeutics trading resumes
09:38 EDT LENZ Therapeutics (LENZ) trading resumes
Lenz Therapeutics price target raised to $31 from $29 at BofA
BofA raised the firm’s price target on Lenz Therapeutics (LENZ) to $31 from $29 and keeps a Buy rating on the shares. The firm remains “optimistic” on VIZZ launch efforts…
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Lenz Therapeutics (LENZ) to $38 from $48 and keeps a Buy rating on the shares. The firm reduced its…
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Lenz Therapeutics (LENZ) to Neutral from Overweight with a price target of $12, down from $39, following the Q1 report. The company’s pace of new patient starts…
Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)
Reports Q1 revenue $1.9M, consensus $1.76M. “We have made significant progress in the early quarters of launch driving high ECP awareness, growing prescriber experience and confidence with VIZZ, and h...
LENZ Therapeutics Earnings Call Transcript: Q1 2026
Q1 saw 25,000 prescriptions and $1.9M in net revenue, with strong early refill trends and over 10,000 prescribers. SG&A rose due to DTC investment, but cash remains strong. Focus is on accelerating adoption, expanding globally, and maintaining a favorable safety profile.
LENZ Therapeutics Earnings release: Q1 2026
LENZ Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
LENZ Therapeutics Quarterly report: Q1 2026
LENZ Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch throu...
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmol...
LENZ Therapeutics Proxy statement: Proxy filing
LENZ Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
LENZ Therapeutics Proxy statement: Proxy filing
LENZ Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Lenz Therapeutics (LENZ) to $48 from $56 and keeps a Buy rating on the shares. The firm adjusted its Vizz launch estimates…
Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%
LENZ Therapeutics (LENZ) announced that it has submitted a Marketing Authorization Application, MAA, to the United Kingdom’s Medicines and Healthcare products Regulatory Agency, MHRA, for the review a...
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -...
Lenz Therapeutics price target lowered to $26 from $52 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Lenz Therapeutics (LENZ) to $26 from $52 and keeps a Buy rating on the shares.
Lenz Therapeutics price target lowered to $29 from $35 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Lenz Therapeutics (LENZ) to $29 from $35 and keeps a Buy rating on the shares. After having updated its model…
LENZ Therapeutics Earnings Call Transcript: Q4 2025
LNZ100/VIZZ is off to a strong launch, with robust physician adoption, high refill rates, and encouraging early patient persistence. Financially, the company is well-capitalized, investing heavily in sales, marketing, and DTC campaigns, with expectations for accelerated growth in the second half of 2026.
LENZ Therapeutics Annual report: Q4 2025
LENZ Therapeutics has published its Q4 2025 annual report on March 24, 2026.
LENZ Therapeutics Earnings release: Q4 2025
LENZ Therapeutics released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.